Moreover, treatment of MYD88-mutated WM and MYD88/CD79B ABC DLBCL cell lines with tamatinib or entospletinib showed killing at pharmacologically achievable levels for either agent (Fig. 5b)21,25. This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.